News & Sentiment
LINC Investors Have Opportunity to Lead Lincoln Educational Services Corporation Securities Fraud Lawsuit
NEW YORK, Oct. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lincoln Educational Services Corporation (NASDAQ: LINC) between May 11, 2026 and August 9, 2026, inclusive (the "Class Period"), of the important November 10,...
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
756 articles
Eightpoint Announces Three-Year Beach Cleanup Sponsorship with Plastic Free Cayman
New sponsorship will support 12 beach cleanups over three years, helping protect the Cayman Islands' coastline through community action. GEORGE TOWN,...
📰
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
📰
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
📰
Top Research Reports for Alphabet, ExxonMobil & Toyota Motor
Alphabet, ExxonMobil and Toyota Motor headline today's top research reports, highlighting AI growth, energy cash generation and hybrid vehicle...
📰
HCA (HCA) Q3 2026 Earnings Call Transcript
Volume growth hit 22 consecutive quarters, but payer mix shifts cost $400M in EBITDA.
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin...
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin...
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin...
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin...
📰
Centene (CNC) Q3 2026 Earnings Call Transcript
Medicare Advantage reaches breakeven ahead of schedule as Medicaid membership declines.
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and...
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and...
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and...
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and...
📰
HCA (HCA) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended September 2026, it might be worth...
📰
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
📰
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant...
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant...
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant...
📰
AMN vs. TRI: Which Stock Is the Better Value Option?
AMN vs. TRI: Which Stock Is the Better Value Option?
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise...
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise...
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise...
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise...
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.